KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Liabilities (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Total Liabilities for 8 consecutive years, with $107.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 42.82% to $107.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.7 million through Dec 2025, up 42.82% year-over-year, with the annual reading at $107.7 million for FY2025, 42.82% up from the prior year.
  • Total Liabilities hit $107.7 million in Q4 2025 for Castle Biosciences, up from $95.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $107.7 million in Q4 2025 to a low of $18.7 million in Q1 2021.
  • Historically, Total Liabilities has averaged $55.6 million across 5 years, with a median of $50.5 million in 2021.
  • Biggest five-year swings in Total Liabilities: tumbled 55.34% in 2021 and later surged 151.21% in 2022.
  • Year by year, Total Liabilities stood at $50.8 million in 2021, then fell by 5.22% to $48.2 million in 2022, then grew by 28.83% to $62.1 million in 2023, then grew by 21.47% to $75.4 million in 2024, then surged by 42.82% to $107.7 million in 2025.
  • Business Quant data shows Total Liabilities for CSTL at $107.7 million in Q4 2025, $95.7 million in Q3 2025, and $89.4 million in Q2 2025.